Biomarkers and Imaging Markers for ICH
Key facts
- Who runs it
- Southwest Hospital, China
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 200 people, planned
- Started
- 1 Jan 2014
- Expected to end
- 1 Dec 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- body sample collection and imaging scan
- Record updated
- 17 June 2024
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Individuals aged 18-80 years
- Hematoma size is more than 5 ml
- Evidence of a spontaneous ICH on CT scan
- Patient within 72 hours of ictus
- Glasgow Coma Scale (GCS) Score of 5-15
- The history of hypertension
Who cannot take part
- If the haematological effects of any previous anticoagulants are not completely reversed
- Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases
- Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction
- Individuals with age < 18 years or > 80 years
- ICH secondary to tumor or trauma
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.
The 2 groups in the trial
- ICH group
Patients with CT-demonstrated Intracerebral Hemorrhage (ICH) within 72 hours after symptom onset admitted to Southwest hospital.
Treatment: body sample collection and imaging scan
- Control group
Age- and sex-matched healthy individuals were recruited from volunteers.
Treatment: body sample collection and imaging scan
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Biomarkers and Imaging Markers Screening for Intracerebral Hemorrhage Patients
- Criteria questions
- Built from NCT06462274, who can take part
- Record updated
- 17 June 2024